Phosphodiesterase-5 Inhibitors As Therapeutics for Cardiovascular Diseases: A Brief Review

Overview

Journal Iran J Public Health

Date 2023 Jul 24

PMID 37484720

Authors

Milena Corbic

Jasmina Sretenovic

Vladimir Zivkovic

Vladimir Jakovljevic

Tamara Nikolic Turnic

Affiliations

Soon will be listed here.

Abstract

Background: Three selective and most used inhibitors of PDE-5-sildenafil, vardenafil and tadalafil- have been successfully used for the treatment of erectile dysfunction. Erectile dysfunction and cardiovascular diseases might be considered as two dissimilar clinical signs of the identical systemic disease. PDE-5 inhibitors can through different models and mechanisms induce vasodilation, decrease apoptosis and cell proliferation, and they are widely present in various tissues that make them promising targets in a range of cardiovascular diseases.

Methods: PubMed was explored to identify papers published from 1990-2019, presenting data for the most used PDE-5 inhibitors (sildenafil, tadalafil or vardenafil) in treatment of cardiovascular diseases.

Results: This article analyses the therapeutic potentials of PDE-5 inhibitors in cardiovascular diseases and discusses mechanisms, possible risks and limitations. Comparable to earlier studies, newer studies suggest cardioprotective effects of PDE-5 inhibitors, which include different models and mechanisms and do not indicate an increased rate of significant cardiovascular adverse reactions. Dissimilarity in the pharmacokinetics and pharmacodynamics of PDE-5 inhibitors are significant to their risk- benefit profile and clinical use. Some of the studies suggesting infarct size reduction after PDE-5 inhibition described the especially close dose-effect relation, other studies dosage adaptation in drug- drug interactions.

Conclusion: PDE-5 inhibitors indicate the encouraging useful effects by ischemia/reperfusion injury, myocar-dial infarction, cardiac hypertrophy, cardiomyopathy and systolic and diastolic congestive heart failure. Therefore, this and similar reviews can help for additional clinical targeting in the therapy of cardiovascular diseases.

References

Nagy O, Hajnal A, Parratt J, Vegh A . Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs. Br J Pharmacol. 2004; 141(4):549-51. PMC: 1574240. DOI: 10.1038/sj.bjp.0705658. View

Seo K, Rainer P, Lee D, Hao S, Bedja D, Birnbaumer L . Hyperactive adverse mechanical stress responses in dystrophic heart are coupled to transient receptor potential canonical 6 and blocked by cGMP-protein kinase G modulation. Circ Res. 2014; 114(5):823-32. PMC: 3963144. DOI: 10.1161/CIRCRESAHA.114.302614. View

McAlindon E, Bucciarelli-Ducci C, Suleiman M, Baumbach A . Infarct size reduction in acute myocardial infarction. Heart. 2014; 101(2):155-60. DOI: 10.1136/heartjnl-2013-304289. View

Chiang C, Luk H, Wang T, Ding P . Effects of sildenafil on cardiac repolarization. Cardiovasc Res. 2002; 55(2):290-9. DOI: 10.1016/s0008-6363(02)00438-8. View

Salloum F, Yin C, Xi L, Kukreja R . Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res. 2003; 92(6):595-7. DOI: 10.1161/01.RES.0000066853.09821.98. View

Dias A, Leal M, Zanardo T, Alves G, Porto M, Nogueira B . Beneficial Morphofunctional Changes Promoted by Sildenafil in Resistance Vessels in the Angiotensin II-Induced Hypertension Model. Curr Pharm Biotechnol. 2018; 19(6):483-494. DOI: 10.2174/1389201019666180625094704. View

Li F, Jiang Q, Shi K, Luo H, Yang Y, Xu C . RhoA modulates functional and physical interaction between ROCK1 and Erk1/2 in selenite-induced apoptosis of leukaemia cells. Cell Death Dis. 2013; 4:e708. PMC: 3730416. DOI: 10.1038/cddis.2013.243. View

Lux A, Pokreisz P, Swinnen M, Caluwe E, Gillijns H, Szelid Z . Concomitant Phosphodiesterase 5 Inhibition Enhances Myocardial Protection by Inhaled Nitric Oxide in Ischemia-Reperfusion Injury. J Pharmacol Exp Ther. 2015; 356(2):284-92. DOI: 10.1124/jpet.115.227850. View

Halcox J, Nour K, Zalos G, Mincemoyer R, Waclawiw M, Rivera C . The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol. 2002; 40(7):1232-40. DOI: 10.1016/s0735-1097(02)02139-3. View

10.

Kukreja R, Salloum F, Das A, Koka S, Ockaili R, Xi L . Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. Exp Clin Cardiol. 2011; 16(4):e30-5. PMC: 3206106. View

11.

Andersson D, Trolle Lagerros Y, Grotta A, Bellocco R, Lehtihet M, Holzmann M . Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart. 2017; 103(16):1264-1270. PMC: 5537549. DOI: 10.1136/heartjnl-2016-310746. View

12.

Kloner R, Rezkalla S . Preconditioning, postconditioning and their application to clinical cardiology. Cardiovasc Res. 2006; 70(2):297-307. DOI: 10.1016/j.cardiores.2006.01.012. View

13.

Salloum F, Abbate A, Das A, Houser J, Mudrick C, Qureshi I . Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol. 2008; 294(3):H1398-406. DOI: 10.1152/ajpheart.91438.2007. View

14.

Halestrap A, Clarke S, Javadov S . Mitochondrial permeability transition pore opening during myocardial reperfusion--a target for cardioprotection. Cardiovasc Res. 2004; 61(3):372-85. DOI: 10.1016/S0008-6363(03)00533-9. View

15.

Westermann D, Becher P, Lindner D, Savvatis K, Xia Y, Frohlich M . Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. Basic Res Cardiol. 2012; 107(6):308. DOI: 10.1007/s00395-012-0308-y. View

16.

Guazzi M, Vicenzi M, Arena R, Guazzi M . Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011; 124(2):164-74. DOI: 10.1161/CIRCULATIONAHA.110.983866. View

17.

DAndrea S, Barbonetti A, Martorella A, Necozione S, Francavilla F, Francavilla S . Effect of prolonged treatment with phosphodiesterase-5-inhibitors on endothelial dysfunction in vascular diseases and vascular risk conditions: A systematic review analysis and meta-analysis of randomized double-blind placebo-controlled trials. Int J Clin Pract. 2018; 73(2):e13296. DOI: 10.1111/ijcp.13296. View

18.

Koka S, Das A, Zhu S, Durrant D, Xi L, Kukreja R . Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. J Pharmacol Exp Ther. 2010; 334(3):1023-30. PMC: 2939673. DOI: 10.1124/jpet.110.170191. View

19.

Prysyazhna O, Burgoyne J, Scotcher J, Grover S, Kass D, Eaton P . Phosphodiesterase 5 Inhibition Limits Doxorubicin-induced Heart Failure by Attenuating Protein Kinase G Iα Oxidation. J Biol Chem. 2016; 291(33):17427-36. PMC: 5016139. DOI: 10.1074/jbc.M116.724070. View

20.

Bender A, Beavo J . Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006; 58(3):488-520. DOI: 10.1124/pr.58.3.5. View